Monoclonal antibodies in cancer immunotherapy

被引:139
作者
Kimiz-Gebologlu, Ilgin [1 ]
Gulce-Iz, Sultan [1 ,2 ,3 ]
Biray-Avci, Cigir [4 ]
机构
[1] Ege Univ, Inst Nat & Appl Sci, Bioengn Grad Programme, Izmir, Turkey
[2] Ege Univ, Dept Bioengn, Fac Engn, Izmir, Turkey
[3] Ege Univ, Biomed Technol Grad Programme, Inst Nat & Appl Sci, Izmir, Turkey
[4] Ege Univ, Med Sch, Dept Med Biol, Izmir, Turkey
关键词
Immunotherapy; Monoclonal antibody; Cancer; Treatment; THERAPEUTIC ANTIBODIES; CYTOTOXICITY ACTIVITY;
D O I
10.1007/s11033-018-4427-x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Nowadays, in cancer treatments, immunotherapy which can be classified as a cancer type specific therapy is more popular than non-specific therapy methods such as surgery, radiotherapy and chemotherapy. The main aim of immunotherapy is to enable patients' immune system to target cancer cells and destroy them. The mainly used treatment methods in cancer immunotherapy are cancer vaccines, adoptive cell therapy, cytokines and monoclonal antibodies. In this review, we discuss the immunotherapy approaches, especially monoclonal antibodies which are mostly used in cancer immunotherapy in clinical applications.
引用
收藏
页码:2935 / 2940
页数:6
相关论文
共 45 条
[41]  
Teillaud Jean-Luc, 2012, Methods Mol Biol, V911, P3, DOI 10.1007/978-1-61779-968-6_1
[42]  
Visagie M, 2010, BIOMED RES-INDIA, V21, P377
[43]   NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy [J].
Wang, Wei ;
Erbe, Amy K. ;
Hank, Jacquelyn A. ;
Morris, Zachary S. ;
Sondel, Paul M. .
FRONTIERS IN IMMUNOLOGY, 2015, 6
[44]   Monoclonal antibodies: versatile platforms for cancer immunotherapy [J].
Weiner, Louis M. ;
Surana, Rishi ;
Wang, Shangzi .
NATURE REVIEWS IMMUNOLOGY, 2010, 10 (05) :317-327
[45]   The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy [J].
Zhou, Xuhui ;
Hu, Weiguo ;
Qin, Xuebin .
ONCOLOGIST, 2008, 13 (09) :954-966